Skip to main content
. 2009 Nov 24;101(11):1817–1823. doi: 10.1038/sj.bjc.6605428

Figure 1.

Figure 1

The figure shows that having at least one copy of the CYP2C8*3 allele conferred an increased risk for an early breast cancer-related event in tamoxifen-treated women with invasive ER-positive cancers (log rank 4.47; 1 df; P=0.034). HR 9.10 (95% CI 1.39-59.6; P=0.021), adjusted for invasive tumour size, age, PR, histological grade, axillary lymph node status, CYP2C8*4, CYP2C9*2, and CYP2C9*3. The number of patients at each time point is indicated.